Apollon Formulations Kill Triple-Negative Breast Cancer (TNBC) Cells Apollon Formularies plc (AQSE: APOL) ( Apollon or the Company ), a UK based international pharmaceutical company trading on Aquis Stock Exchange, is pleased to announce that its proprietary medical cannabis formulations were successful in killing triple-negative breast cancer (TNBC) cells in 3D cell cultures in third party independent laboratory testing. This finding is in addition to the results recently announced on May 18, 2021, that Apollon formulations were successful in killing HER2+ breast cancer cells. This testing was performed under a joint testing agreement with Aion Therapeutic Inc. (CSE: AION) ( Aion ), a BC based international pharmaceutical company trading on the Canadian Securities Exchange.
Hold Off on Approving Anal Cancer Drug, Advisors Tell FDA
medpagetoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medpagetoday.com Daily Mail and Mail on Sunday newspapers.
FDA issues draft guidance encouraging rational expanded patient eligibility for oncology clinical trials
news-medical.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from news-medical.net Daily Mail and Mail on Sunday newspapers.
Hold Off on Approving Anal Cancer Drug, Advisors Tell FDA
medpagetoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medpagetoday.com Daily Mail and Mail on Sunday newspapers.
FDA issues guidance for measuring PROs in oncology studies
outsourcing-pharma.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from outsourcing-pharma.com Daily Mail and Mail on Sunday newspapers.